Tesamorelin
Studied for: gHRH analog
Tesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.
Last reviewed September 26, 2026
How it is thought to work
Research describes tesamorelin as a modified GHRH analog with greater stability than the native hormone, studied for pituitary action and downstream metabolic signaling.
- Stabilized AnalogStudied as a modified releasing-hormone analog engineered for greater stability in research settings.
- Body CompositionExplored in research on visceral adipose tissue and associated metabolic markers.
- Route studied
- Subcutaneous
- Receptor class
- GHRH-R
- Research status
- Late clinical
Published reviews describe human clinical research on tesamorelin as a growth hormone-releasing factor analogue, particularly in HIV-associated lipodystrophy.
Research
What the research covers
What research examines
- Visceral adipose tissue in HIV-associated lipodystrophy
- Endogenous GHRH receptor signaling and pituitary action
- Downstream metabolic markers linked to body composition
- Muscle preservation within body-composition research
- Peptide use in sports medicine and musculoskeletal contexts
Reported effects in studies
- Adverse event profiles are covered in clinical reviews but are not summarized here
- Human safety data for research-grade material outside clinical trials are limited
- Safety of approved and unapproved peptides in athletic settings has been reviewed as an open question
Studied range
What research protocols have used
Research protocols have used 500–2,000 mcg per administration, once daily (pre-sleep), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profile$119
- TirzepatideTirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.Read profile$139
- AOD-9604AOD 9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, isolated for research into fat metabolism without the broader activity of the full hormone.Read profile$89
- 5-Amino-1MQ5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, an enzyme associated with fat-cell metabolism and cellular NAD+ availability.Read profile$89
Studies
Cited research
- Tesamorelin, a human growth hormone releasing factor analogue.
Expert opinion on investigational drugs · 2009 · Review · PMID 19243281
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
The Annals of pharmacotherapy · 2012 · Review · PMID 22298602
- Tesamorelin.
2012 · Review · PMID 31644039
- Tesamorelin.
Nature reviews. Drug discovery · 2011 · PMID 21283099
- Tesamorelin update.
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · 2010 · PMID 21591600
FAQ
Questions about Tesamorelin
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It has been modified to be more stable than the native hormone while retaining activity at the GHRH receptor. Published reviews describe it as a human growth hormone releasing factor analogue, and research has examined its role in endogenous GHRH signaling and its association with visceral adipose tissue. It is supplied by CoreX for laboratory research use only.
Research describes tesamorelin as acting on the GHRH receptor (GHRH-R) at the pituitary, the same target as the native releasing hormone. Its structural modifications are intended to give it greater stability than endogenous GHRH. Studies have focused on this pituitary action and on downstream metabolic signaling, including effects associated with growth hormone release and changes in body composition markers such as visceral fat.
The best-documented research area is HIV-associated lipodystrophy, where reviews describe tesamorelin's study in relation to visceral adipose tissue. Research has also examined associated metabolic markers and the broader question of muscle preservation within body-composition work. More recent reviews in orthopaedic and sports medicine literature discuss tesamorelin alongside other injectable peptides, while noting that evidence in those settings is more limited than in its primary clinical research area.
Clinical reviews of tesamorelin discuss its adverse event profile from human studies, but those findings are not summarized on this page. Human safety data outside controlled clinical research, including for research-grade material, are limited. Reviews of approved and unapproved peptide therapies in musculoskeletal and athletic contexts have highlighted safety and efficacy as areas where further evidence is needed. Findings from specific trial populations should not be generalized to other settings.
Research protocols have used 500 to 2,000 mcg per administration, given once daily before sleep by the subcutaneous route, in 8-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference, and the compound is sold for research use only.
Ask about Tesamorelin
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- Tesamorelin vs CJC-1295Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs studied for their action on pituitary GHRH receptors. Tesamorelin is described in research as a modified GHRH analog engineered for greater stability than the native hormone, and published reviews describe human clinical research on it, particularly on visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 without DAC, also called modified GRF 1-29, is characterized by a short half-life; without the drug affinity complex its action is brief, which research associates with preserving natural pulsatile growth hormone release. Human data for the no-DAC form are limited, appearing mainly in reviews and anti-doping detection research, while a small randomized trial studied the long-acting DAC form in healthy adults.